EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

William H K Schilling iD, Podjanee Jittamala, James A Watson iD, Maneerat Ekkapongpisit, Tanaya Siripoon, Thundon Ngamprasertchai, Viravarn Luvira iD, Sasithorn Pongwilai, Cintia Cruz iD, James J Callery iD, Simon Boyd, Varaporn Kruabkontho und 26 weitere

eLife · 2023

DOI: 10.7554/elife.83201 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift eLife, 2023. Verfasst von William H K Schilling und 37 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has clinically significant antiviral activity in vivo is uncertain.

Methods

In a multicentre open label, randomized, controlled adaptive platform trial, adult patients with early symptomatic COVID-19 were randomized to one of six treatment arms including high-dose oral ivermectin (600 µg/kg daily for 7 days), the monoclonal antibodies casirivimab and imdevimab (600 mg/600 mg), and no study drug. The primary outcome was the comparison of viral clearance rates in the modified intention-to-treat population. This was derived from daily log 10 viral densities in standardized duplicate oropharyngeal swab eluates. This ongoing trial is registered at https://clinicaltrials.gov/ (NCT05041907).

Results

Randomization to the ivermectin arm was stopped after enrolling 205 patients into all arms, as the prespecified futility threshold was reached. Following ivermectin, the mean estimated rate of SARS-CoV-2 viral clearance was 9.1% slower (95% confidence interval [CI] –27.2% to +11.8%; n=45) than in the no drug arm (n=41), whereas in a preliminary analysis of the casirivimab/imdevimab arm it was 52.3% faster (95% CI +7.0% to +115.1%; n=10 (Delta variant) vs. n=41).

Conclusions

High-dose ivermectin did not have measurable antiviral activity in early symptomatic COVID-19. Pharmacometric evaluation of viral clearance rate from frequent serial oropharyngeal qPCR viral density estimates is a highly efficient and well-tolerated method of assessing SARS-CoV-2 antiviral therapeutics in vivo. Funding: ‘Finding treatments for COVID-19: A phase 2 multi-centre adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic COVID-19 (PLAT-COV)’ is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator. Clinical trial number: NCT05041907 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AdultHumansSARS-CoV-2IvermectinAntiviral AgentsTreatment Outcome

Stichwörter der Autor:innen

COVID-19antiviralsbayesian hierarchical linear regressionhumanmedicinepharmacometric assessmentrate of viral clearance

Substanzen

IvermectinAntiviral Agents

Autor:innen und Institutionen

  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
  • Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Bangplee Hospital, Ministry of Public Health, Bangkok, Thailand.
  • Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

ORCID-Profile: William H K Schilling, James A Watson, Viravarn Luvira, Cintia Cruz, James J Callery, Janjira Thaipadungpanit, Joel Tarning, Mauro Martins Teixeira, Arjen M Dondorp, Nicholas P J Day, Nicholas J White

Förderung

  • Wellcome Trust

Zitieren

APA

Schilling, W. H. K., Jittamala, P., Watson, J. A., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J. J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., …, & PLATCOV Collaborative Group (2023). Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). eLife. https://doi.org/10.7554/elife.83201

Vancouver

Schilling WHK, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, et al. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). eLife. 2023. doi:10.7554/elife.83201

BibTeX
@article{Schilling2023,
  author = {Schilling, William H K and Jittamala, Podjanee and Watson, James A and Ekkapongpisit, Maneerat and Siripoon, Tanaya and Ngamprasertchai, Thundon and Luvira, Viravarn and Pongwilai, Sasithorn and Cruz, Cintia and Callery, James J and Boyd, Simon and Kruabkontho, Varaporn and Ngernseng, Thatsanun and Tubprasert, Jaruwan and Abdad, Mohammad Yazid and Piaraksa, Nattaporn and Suwannasin, Kanokon and Hanboonkunupakarn, Pongtorn and Hanboonkunupakarn, Borimas and Sookprome, Sakol and Poovorawan, Kittiyod and Thaipadungpanit, Janjira and Blacksell, Stuart and Imwong, Mallika and Tarning, Joel and Taylor, Walter R J and Chotivanich, Vasin and Sangketchon, Chunlanee and Ruksakul, Wiroj and Chotivanich, Kesinee and Teixeira, Mauro Martins and Pukrittayakamee, Sasithon and Dondorp, Arjen M and Day, Nicholas P J and Piyaphanee, Watcharapong and Phumratanaprapin, Weerapong and White, Nicholas J and PLATCOV Collaborative Group, PLATCOV Collaborative Group},
  title = {Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.83201}
}
Kostenlos starten →